In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Goldman Sachs initiated coverage on Viking Holdings (NYSE:VIK) stock, a $20.9 billion market cap cruise operator, with a ...

Viking Therapeutics Inc.’s stock jumped 3% Tuesday, after a bullish note from Oppenheimer highlighted the company’s promising ...

Viking Therapeutics (NASDAQ:VKTX), currently trading at $32.65, remained in focus as H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating with a price target of $102.00. According to ...

Viking Therapeutics (NASDAQ: VKTX) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's share price eroded by 24% in December, primarily on the back of a ...

First, let's get to the bottom of what Merck did to provoke Viking's stock into tumbling so much and so quickly. Merck just signed a licensing deal with a biotech based in China so that it could ...

It's been a volatile year for Viking Therapeutics stock, though good news on the weight-loss-drug front has the healthcare stock up 260% since the start of January. And Wall Street sees even more ...

Viking Therapeutics, Inc. (VKTX) closed at $42.53 in the latest trading session, marking a -0.84% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.55% for ...

While the focus on Viking increases investment volatility, data from competitors or new licensing deals could significantly affect its stock. William Blair remains confident that Viking offers a ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that ...